Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials

Johnson & Johnson Inc. JNJ

Johnson & Johnson (NYSE:JNJ) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) on Wednesday released new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies of icotrokinra compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis.

Icotrokinra met both co-primary endpoints compared to placebo at Week 16 with similar adverse event rates and showed superiority to Bristol-Myers Squibb & Co.’s (NYSE:BMY) Sotyktu (deucravacitinib) at multiple timepoints in adult patients.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.